TMCnet - World's Largest Communications and Technology Community



Personalized Medicines - Global Strategic Business Report 2014-2020: Adverse Drug Reactions of Prescription Drugs Drive Personalized Medicine Market
[May 19, 2014]

Personalized Medicines - Global Strategic Business Report 2014-2020: Adverse Drug Reactions of Prescription Drugs Drive Personalized Medicine Market

(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets ( has announced the addition of the "Personalized Medicines - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Product Segments: Targeted Therapeutics, and Tests & Lab Services. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Key Topics Covered: Click the link above to view the extended table of contents I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET GROWTH DRIVERS AND RESTRAINTS - Growth Drivers in a Gist - Key Market Restraints - Increasing Incidence and Prevalence of CDDs: A Major Growth Driver - Ballooning Global Population Offers Significant Growth Opportunities 3. PERSONALIZED MEDICINE MARKET TRENDS & CHALLENGES - Changing Patients' Trends Drive Personalized Medicine - Adverse Drug Reactions of Prescription Drugs Drive Personalized Medicine Market - List of Top 10 Drugs with Adverse Drug Reactions - Genomics to Dictate Advancement of Personalized Medicines - Investors' Interest Personalized Medicines Gathers Steam 4. ONCOLOGY: A MAJOR PERSONALIZED MEDICINE MARKET 5. SELECT TECHNOLOGICAL ADVANCEMENTS - NanoVelcro Chip Device - Enhanced to Personalize Treatment for Prostate Cancer - Development of New Cancer Treatment Method for Personalized Cancer Therapy - Gene Therapy using a Pill for Treating Cancer - New Ways of Offering Personalized Cancer Treatments 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS AND APPROVALS - NMTC Launches Expanded Personalized Medicine Panel Created on Luminex's xMAP Technology - Dako to Introduce New Antibody to Diagnose Breast Cancer - bioM?rieux's New Generation VIDAS? 3 Obtains CE Marking - GSK's Two New Single-Agent Oral Oncology Treatments Receive FDA Approval - Dako Obtains FDA Approval for Two Companion Diagnostic Assays for Genentech's Kadcyla - Genentech Receives FDA Approval for Kadcyla Drug - Dako's FISH Assay for Cancer Diagnostics Obtains FDA Approval - Luminex Receives US FDA Approval for MAGPIX? Instrument with xTAG GPP - QIAGEN Obtains FDA Approval for Marketing therascreen? KRAS RGQ PCR Kit - Roche Gains Approval from EMA for PERJETA - OGT Unveils SureSeq Solid Tumor Panel Sequencing Service - Abbott Launches Hepatitis C Virus Genotyping Test 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS - Abbott Molecular, Inc. (US) - Affymetrix, Inc. (US) - AstraZeneca plc (UK) - Bayer HealthCare Pharmaceuticals (Germany) - Beckman Coulter Genomics (US) - bioM?rieux SA (France) - Clarient, Inc. (US) - Dako Denmark A/S (Denmark) - F. Hoffmann-La Roche Ltd. (Switzerland) - GlaxoSmithKline plc. (UK) - Hologic, Inc. (US) - IRIS Personalized Medicine (US) - Lab 21 Limited (UK) - Macrogen, Inc. (Korea) - QIAGEN NV (The Netherlands) - Rosetta Genomics Ltd (Israel) 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 85 (including Divisions/Subsidiaries 93) - The United States (64) - Canada (2) - Japan (1) - Europe (20) - France (5) - Germany (5) - The United Kingdom (6) - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (3) - Latin America (1) - Middle East (2) For more information visit CONTACT: Research and Markets, Laura Wood, Senior Manager. Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Pharmaceuticals ( .


[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy